For Immediate Release
Chicago, IL –November 1, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Citigroup (C - Free Report) , Novo Nordisk (NVO - Free Report) , BP (BP - Free Report) , salesforce.com (CRM - Free Report) and TC Energy (TRP - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Citigroup, Novo Nordisk and BP
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Citigroup (C - Free Report) , Novo Nordisk and BP. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Citigroup’s shares have outperformed the Zacks Major Regional Banks industry year to date (40.2% vs. 24.3%). The Zacks analyst believes that third-quarter results reflected revenue strength, along with rising loan and deposit balance.
Also, escalated investment banking revenues and reduced volumes and client activity levels were recorded in the quarter. Citigroup’s streamlining efforts, along with strategic investments in core business, bode well for the long term. Also, a declining cost base will support bottom-line improvement.
Citigroup's steady capital-deployment activities are also commendable depicting a strong capital position. However, pending litigation issues might keep legal expenses elevated. Further, decline in fee income is another concern for the company.
(You can read the full research report on Citigroup here >>>)
Shares of Novo Nordisk have gained 13.3% in the past six months against the Zacks Biotech industry’s rise of 4.3%. The Zacks analyst believes that solid performances from Tresiba, Victoza, Ozempic, Xultophy and Saxenda have driven the company’s sales in the year so far.
Label expansion of Victoza continues to boost performance. Ozempic, the company’s once-weekly GLP-1, continues to gain market share. The FDA recently approved semaglutide in tablet form under the brand name, Rybelsus. The company continues to evaluate the candidate for multiple indications.
However, lower realized prices in the Unites States, loss of exclusivity for products in hormone replacement therapy and intensifying competition within the diabetes and biopharmaceuticals markets will adversely impact sales going forward.
(You can read the full research report on Novo Nordisk here >>>)
BP’s shares have lost 1.4% over the past three months against the Zacks International Integrated Oil industry’s fall of 1.9%. The Zacks analyst believes that BP has been gaining from a strong portfolio of upstream projects.
Since 2016, BP has placed 23 key upstream developments online, which will help the British energy giant boost production by 900 thousand barrel of oil equivalent per day (MBOE/D) by 2021. In fact, production from these key projects has helped the integrated energy major report better-than-expected earnings for the third quarter. Moreover, the company is strongly committed toward returning cash to its shareholders.
However, the 2010 oil spill incident in the BP-operated Macondo Prospect is still affecting the firm. Although BP has cleared the huge litigation expenses related to the spill, it had to divest some of its best operating properties. Also, the company expects refining margins in the December quarter of 2019 to drop sequentially owing to continued turnaround activities.
(You can read the full research report on BP here >>>)
Other noteworthy reports we are featuring today include salesforce.com and TC Energy.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Download Free Report Now >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.